Quantcast Acelity - PROMOGRAN PRISMA™ Matrix
MENU

PROMOGRAN PRISMA™ Matrix

The information on this page is intended for healthcare professionals. Patient-specific information is available in the “Patients” section of this site. Patients should consult a healthcare professional regarding specific medical conditions and treatments.

PROMOGRAN PRISMA™ Matrix
PROMOGRAN PRISMA™ Matrix

A Clinically Proven Combination

PROMOGRAN PRISMA™ Matrix is comprised of a sterile, freeze dried composite of 44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC. Silver-ORC contains 25 % w/w ionically bound silver, a well-known antimicrobial agent.
Optimum wound environment
PROMOGRAN PRISMA™ Matrix maintains a physiologically moist microenvironment at the wound surface. This environment is conducive to granulation tissue formation, epithelization and optimal wound healing. Ionically-bound silver is an antimicrobial agent.
 
Clinically Proven
The efficacy of PROMOGRAN PRISMA™ Matrix is supported by a body of clinical evidence, including 1 published RCT1.
 

How it Works

  • About
  • Materials For Download

About

Maintains an optimum wound-healing environment

In the presence of exudate, PROMOGRAN PRISMA™ Matrix transforms into a soft, conformable, biodegradable gel, allowing contact with all areas of the wound.
 
PROMOGRAN PRISMA™ Matrix maintains a physiologically moist microenvironment at the wound surface. This environment is conducive to granulation tissue formation, epithelialization and optimal wound healing.
 
  • Optimum wound environment
  • Clinically proven
PROMOGRAN PRISMA™ Matrix How Does It Work
PROMOGRAN PRISMA™ Matrix How Does It Work

Indications & Applications

Indications & Applications

Indications for Use

PROMOGRAN PRISMA™ Matrix is intended for the management of exuding wounds.
 
Under the supervision of a health care professional, PROMOGRAN PRISMA™ Matrix
may be used for the management of:
 
  • Diabetic ulcers
  • Venous ulcers
  • Pressure ulcers
  • Ulcers caused by mixed vascular etiologies
  • Full-thickness and partial thickness wounds
  • Donor sites and other bleeding surface wounds
  • Abrasions
  • Traumatic wounds healing by secondary intention
  • Dehisced surgical wounds
 
Please refer to the full instructions for use in the packaging insert
 

Usage Videos

Evidence & Outcomes

The efficacy of PROMOGRAN PRISMA Matrix is supported by clinical evidence, including a published RCT.
 

Clinical Evidence

Additional summary of evidence and outcomes.

Evidence & Outcomes

Supporting Publications

Title Study Type Date Authors
Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair and Regeneration. 2002 Jan 1;10(1):16-25
Case Study
2014
Cullen B, Smith R, Mcculloch E, Silcock D, Morrison L.
Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. Journal of Wound Care. 2002 Feb 1;11(2):70-74
Economic Study
2013
Ghatnekar O, Willis M, Persson U.
Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment. Wound Repair and Regeneration. 2013 Mar-Apr;21(2):216-25. Epub 2013 Feb 25.
Case Study
2010
Gottrup F, Cullen BM, Karlsmark T, Bischoff-Mikkelsen M, Nisbet L, Gibson MC.
Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. Journal of Diabetes and Its Complications. 2007 Nov 1;21(6):387-391
Prospective Cohort Study
2011
Kakagia DD, Kazakos KJ, Xarchas KC, et al.
Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. Journal of Diabetes and Its Complications. 2006 Sep-Oct;20(5):329-35
Case Study
2010
Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H.
A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Archives of Surgery. 2002 Jul 1;137(7):822-827
Randomized Control Trial
2002
Veves A, Sheehan P, Pham HT.
Wound conditioning of a deep tissue defect including exposed bone after tumour excision using PROMOGRAN* Matrix, a protease-modulating matrix. International Wound Journal. 2005 Sep;2(3):253-7.
Case Study
2005
Tausche AK, Sebastian G.
The healing properties of Promogran in venous leg ulcers. Journal of Wound Care. 2002 Oct 1;11(9):335-341
Case Study
2002
Vin F, Teot L, Meaume S.
Some effects of a topical collagen-based matrix on the microcirculation and wound healing in patients with chronic venous leg ulcers: preliminary observations. International Journal of Lower Extremity Wounds. 2005 Dec 1;4(4):214-224
Prospective Study
2008
Wollina U, Schmidt WD, Kronert C, Nelskamp C, Scheibe A, Fassler D.
Use of a protease-modulating matrix in the treatment of pressure sores. Chirurgia Italiana. 2005 Jul 1;57(4):465-468
Prospective Cohort Study
2005
Nisi G et al.

Ordering Information

Product Codes

Product Item Code Eaches/Carton/Box/HCPCS Code
PROMOGRAN PRISMA™ Matrix
4.34 sq. in. Hexagon
MA028
Box of 40 (4 Cartons of 10)
HCPCS Code A6021
PROMOGRAN PRISMA™ Matrix
19.1 sq. in. Hexagon
MA123
Box of 40 (4 Cartons of 10)
HCPCS Code A6022
Want to learn more? Please call +1 800-275-4524 or click here.

Footer Navigation